Drug intelligence / Profile preview

SHR-3032

Development stage: Phase 1
Lead developer: Hengrui Pharmaceutical
Administration: Intravenous

Overview

SHR-3032 is a biological product developed by Guangdong Hengrui Pharmaceutical. It is being investigated for the prevention of graft rejection, primarily in the context of transplantation. The drug is administered intravenously and has completed Phase 1 clinical trials evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects. The precise mechanism of action remains undisclosed or unknown as of the latest available data[1][2][10].

Beyond the preview

Go deeper on SHR-3032.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR-3032.

Explore the full profile